AMBEV S.A. current report, Q4 FY2023

Business Context and Reporting Period

This Form 6-K filing by Ambev S.A. covers the reporting period of September 1, 2023, to September 30, 2023. The document serves as a consolidated report of securities transactions conducted by the company's Board of Directors, Management, and Fiscal Council, filed in compliance with Article 11 of CVM Instruction # 358/2002. The report was signed on October 9, 2023.

Key Financial Metrics

This filing is a regulatory disclosure of insider trading activity and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any operational or financial KPIs.

Material Changes and Transactions

The filing details specific changes in securities holdings for three distinct groups during September 2023:

  • Board of Directors: No transactions occurred. The group held an initial and final balance of 10,782,599 Common Shares and 500,000 ADRs.
  • Management:
    • Exits (Sales/Renunciations): Sold 25,000 ADRs via JP Morgan (Volume: R$ 339,109.25) and 1,300 Common Shares via Itaú (Volume: R$ 18,330.00). Additionally, 56,377 Common Shares were renounced.
    • Entries: Acquired 43,865 Common Shares via election (Price: R$ 0.00).
    • Net Position Change: Common Shares decreased from 2,191,451 to 2,177,639. ADRs decreased from 70,885 to 45,885.
  • Fiscal Council: No transactions occurred. The group held an initial and final balance of 2,000 Common Shares.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly limited to the reporting of historical securities transactions.

Investor Verification Checklist

  • Verify the total volume of Management sales (R$ 357,439.25) against the company's overall trading volume for September 2023.
  • Confirm the impact of the 56,377 renounced shares on the total outstanding share count.
  • Review the price per ADR (R$ 13.56) and Common Share (R$ 14.10) to assess the valuation at the time of the transaction.
  • Check subsequent filings to determine if the Board of Directors or Fiscal Council engaged in transactions in the following month.